Using gut microbiome tests and stool transfer in immunotherapy cancer
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial studies whether changes in gut bacteria can help predict how well immunotherapy works for solid cancers. It also tests whether stool (fecal microbiota) from certain immunotherapy-responding people can improve outcomes for others who are not responding well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 or older and have a confirmed solid cancer
- You are currently on immunotherapy or will start it soon
- Your cancer has at least one measurable spot that doctors can track
- You cannot have active infections like HIV or tuberculosis
- You should not have an autoimmune disease that needs treatment (some exceptions like thyroid hormone replacement)
- For the stool-transfer part: you must be eligible for colonoscopy and your cancer must be progressing on immunotherapy in a specific way
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether transferring stool microbiome (“FMT,” stool transplant) along with nivolumab can improve outcomes in people with advanced solid cancers that kept worsening even after anti–PD-1/PD-L1 treatment. It also looks at stool and blood changes to understand why the treatment might work.
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
This study looks at how gut bacteria may relate to how well immunotherapy works in people with advanced or returning gynecologic cancer. You may be asked to give stool samples several times so researchers can measure changes in your gut microbiome.
This trial tests whether transferring healthy gut bacteria can help make immunotherapy more effective for people with advanced bowel cancer that didn't respond to standard treatments.
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
Hear when a new Solid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.